Equities research analysts predict that Incyte Co. (NASDAQ:INCY) will post $412.85 million in sales for the current quarter, according to Zacks Investment Research. Twenty analysts have made estimates for Incyte’s earnings, with estimates ranging from $374.55 million to $486.65 million. Incyte reported sales of $326.50 million during the same quarter last year, which indicates a positive year-over-year growth rate of 26.4%. The business is scheduled to report its next earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that Incyte will report full year sales of $412.85 million for the current financial year, with estimates ranging from $1.47 billion to $1.56 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.76 billion per share, with estimates ranging from $1.52 billion to $1.96 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Incyte.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. During the same quarter last year, the firm earned $0.19 EPS. Incyte’s revenue for the quarter was up 41.6% compared to the same quarter last year.

INCY has been the subject of a number of analyst reports. Deutsche Bank initiated coverage on Incyte in a research note on Tuesday, December 12th. They issued a “hold” rating and a $106.00 price target for the company. BMO Capital Markets decreased their price target on Incyte from $163.00 to $162.00 and set an “outperform” rating for the company in a research note on Thursday, October 26th. Zacks Investment Research downgraded Incyte from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Raymond James Financial restated a “buy” rating on shares of Incyte in a research note on Tuesday, December 12th. Finally, Royal Bank of Canada decreased their price target on Incyte from $136.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 21st. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Incyte presently has an average rating of “Buy” and an average price target of $143.11.

Incyte (NASDAQ:INCY) opened at $90.31 on Thursday. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. Incyte has a one year low of $88.81 and a one year high of $153.15.

In other news, EVP Vijay K. Iyengar sold 5,000 shares of Incyte stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total transaction of $486,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David W. Gryska sold 3,915 shares of Incyte stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The disclosure for this sale can be found here. Insiders have sold a total of 44,878 shares of company stock valued at $4,636,494 over the last quarter. 17.70% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Incyte by 11.1% in the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock valued at $2,156,276,000 after purchasing an additional 1,709,685 shares during the period. Manning & Napier Advisors LLC bought a new stake in Incyte in the 3rd quarter valued at $125,065,000. Janus Henderson Group PLC boosted its stake in Incyte by 4,570.1% in the 2nd quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock valued at $131,622,000 after purchasing an additional 1,022,979 shares during the period. Old Mutual Global Investors UK Ltd. boosted its stake in Incyte by 374.4% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 930,319 shares of the biopharmaceutical company’s stock valued at $108,605,000 after purchasing an additional 734,235 shares during the period. Finally, Matrix Capital Management Company LP boosted its stake in Incyte by 28.3% in the 2nd quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock valued at $226,225,000 after purchasing an additional 396,716 shares during the period. Institutional investors own 90.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Incyte Co. (INCY) Will Post Quarterly Sales of $412.85 Million” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-expect-incyte-co-incy-will-post-quarterly-sales-of-412-85-million.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.